+357 96 030922
info@marketpublishers.com

China Epigenetic Technologies Market Size and Forecast (2021 - 2031), Country Share, Trend, and Growth Opportunity Analysis Report Coverage: By Products and Services (Kits and Reagents, Instruments and Accessories, Enzymes, and Services), Application (Oncology and Non-Oncology), Technology [DNA Methylation Analysis, Chromatin Immunoprecipitation Sequencing (ChIP-Seq), Cleavage Under Targets and Tagmentation (CUT and Tag), Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-Seq), Histone Modification Analysis, RNA Epigenetics, Single-cell Epigenomic Assays, and Others], and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others)

https://marketpublishers.com/r/C3FE7B0A401AEN.html
Date: September 2025
Pages: 123
Price: US$ 2,450.00 (Single User License)
ID: C3FE7B0A401AEN

Abstracts

The China epigenetic technologies market size is expected to grow from US$974.40 million in 2024 to US$2,468.42 million by 2031; it is projected to register a CAGR of 14.3% during 2025-2031. The increasing burden of chronic diseases, government funding and strategic support, and advancement in epigenetic technology are noteworthy factors contributing to the expansion of the China epigenetic technologies

+357 96 030922
info@marketpublishers.com

market size. However, the regulatory challenges and high costs of products hinder the China epigenetic technologies market growth.

Multi-omics, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, offers a holistic representation of biological systems. Combined with AI's sophisticated data analysis, it opens the gates to new potential for biomarker identification, drug discovery, and precision medicine. Multi-omics is boosted by AI in that it processes enormous amounts of intricate data to find patterns in epigenetic alterations, like DNA methylation and histone modifications, which control gene expression without changing DNA sequences. In China, national initiatives like the China Precision Medicine Initiative produce enormous omics datasets, which require AI for effective analysis. Machine learning techniques inspect patterns of DNA methylation associated with cancer, facilitating early diagnosis and tailored treatment plans. At Shanghai Municipal Hospital of Traditional Chinese Medicine, AI-powered multi-omics strategies combine epigenetics with other omics information to simulate multi-metabolite relationships in Traditional Chinese Medicine (TCM), refining precision therapies for cancer.

Recent developments reflect China's dominance in this area. In 2024, Shanghai's Epigenic Therapeutics began clinical testing of EPI-003, an antiviral treatment for chronic hepatitis B targeting the liver, with an AI-optimized epigenetic editing platform. The platform involves the use of mRNA encoding epigenetic proteins with guide RNA, reflecting the application of AI in making drug development more efficient. Beijing's genomics programs use AI to combine epigenomic and transcriptomic information, uncovering biomarkers for bladder cancer, among other diseases, where 48 genes with discrete SNPs and CpGs were confirmed, with 75% reproducibility in independent data sets. The combination of epigenetic information with other omics technologies (e.g., genomics, proteomics) and AI optimizes drug discovery and diagnostic development efficiency.

Artificial intelligence-based epigenetic analysis software enhances accuracy and speed in the detection of disease-associated modifications, opening up profitable avenues for solutions with the integration of technology. Partnership, as between drug companies and research organizations, speeds up innovation. AI-based platforms like Ginkgo Bioworks' Datapoints, introduced in September 2024, are being reengineered in China to advance multi-omics data analysis for drug discovery. In summary, the convergence of multi-omics and AI is transforming China's market for epigenetic technologies, providing revolutionary healthcare solutions, thus becoming a notable trend in the China epigenetic technologies market.

+357 96 030922
info@marketpublishers.com

End User-Based Insights

Based on end user, the China epigenetic technologies market is segmented into pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, and others. The pharmaceutical and biotechnology companies segment held the largest China epigenetic technologies market share in 2024. As China transforms into a global hub for biopharmaceutical innovation, pharmaceutical and biotech firms are leveraging epigenetic technologies to develop novel diagnostics and targeted therapies, especially for cancer, neurological disorders, and rare genetic diseases. Chinese companies are transitioning from producing generics to developing innovative treatments. Epigenetics, which focuses on gene expression regulation without altering DNA sequences, has emerged as a crucial area for identifying new therapeutic targets. BeiGene and Hutchmed are incorporating epigenetic platforms into their drug discovery pipelines to design more precise and personalized medicines. These technologies allow companies to explore gene-silencing therapies, histone modification inhibitors, and DNA methylation markers, which are relevant in oncology — a priority area in China due to its rising cancer incidence.

Initiatives such as "Made in China 2025" and the 13th and 14th Five-Year Plans have emphasized innovation in biomedicine and precision medicine, encouraging public-private partnerships and facilitating the growth of biotech startups. In December 2024, Epigenic collaborated with Bayer Co.Lab to provide access to global expertise for developing novel epigenetic solutions. Epigenetic diagnostics are integrated with existing treatments, offering tailored therapeutic approaches that enhance patient outcomes in China's rapidly evolving healthcare landscape, thereby fueling the China epigenetic technologies market growth.

GLOBOCAN is among the primary and secondary sources referred to while preparing the China epigenetic technologies market report.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

10. CHINA EPIGENETIC TECHNOLOGIES MARKET ANALYSIS - BY END USER

11. COMPETITIVE LANDSCAPE

12. INDUSTRY LANDSCAPE

+357 96 030922
info@marketpublishers.com

13. COMPANY PROFILES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: China Epigenetic Technologies Market Size and Forecast (2021 - 2031), Country Share, Trend, and Growth Opportunity Analysis Report Coverage: By Products and Services (Kits and Reagents, Instruments and Accessories, Enzymes, and Services), Application (Oncology and Non-Oncology), Technology [DNA Methylation Analysis, Chromatin Immunoprecipitation Sequencing (ChIP-Seq), Cleavage Under Targets and Tagmentation (CUT and Tag), Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-Seq), Histone Modification Analysis, RNA Epigenetics, Single-cell Epigenomic Assays, and Others], and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others)

Product link: https://marketpublishers.com/r/C3FE7B0A401AEN.html

Price: US$ 2,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C3FE7B0A401AEN.html